BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Journal of Hepatology 2019;71:823-33. [DOI: 10.1016/j.jhep.2019.04.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hundertmark J, Tacke F. How effective are nonalcoholic fatty liver disease models for drug discovery? Expert Opin Drug Discov 2020;15:1237-40. [PMID: 32524859 DOI: 10.1080/17460441.2020.1776258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
5 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Reference Citation Analysis]
6 Rowe IA. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. Semin Liver Dis 2020;40:339-45. [PMID: 32906165 DOI: 10.1055/s-0040-1709491] [Reference Citation Analysis]
7 Ferrusquía-acosta J, Bassegoda O, Turco L, Reverter E, Pellone M, Bianchini M, Pérez-campuzano V, Ripoll E, García-criado Á, Graupera I, García-pagán JC, Schepis F, Senzolo M, Hernández-gea V. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. Journal of Hepatology 2021;74:811-8. [DOI: 10.1016/j.jhep.2020.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2021;41:1576-91. [PMID: 33896117 DOI: 10.1111/liv.14899] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Kostrzewski T, Snow S, Battle AL, Peel S, Ahmad Z, Basak J, Surakala M, Bornot A, Lindgren J, Ryaboshapkina M, Clausen M, Lindén D, Maass C, Young LM, Corrigan A, Ewart L, Hughes D. Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. Commun Biol 2021;4:1080. [PMID: 34526653 DOI: 10.1038/s42003-021-02616-x] [Reference Citation Analysis]
10 Nachit M, Kwanten WJ, Thissen JP, Op De Beeck B, Van Gaal L, Vonghia L, Verrijken A, Driessen A, Horsmans Y, Francque S, Leclercq IA. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. J Hepatol 2021;75:292-301. [PMID: 33865909 DOI: 10.1016/j.jhep.2021.02.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Lefere S, Puengel T, Hundertmark J, Penners C, Frank AK, Guillot A, de Muynck K, Heymann F, Adarbes V, Defrêne E, Estivalet C, Geerts A, Devisscher L, Wettstein G, Tacke F. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J Hepatol 2020;73:757-70. [PMID: 32360434 DOI: 10.1016/j.jhep.2020.04.025] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
12 Okanoue T, Sakamoto M, Harada K, Inagaki M, Totsuka N, Hashimoto G, Kumada H. Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study. Hepatol Res 2021;51:943-56. [PMID: 34260795 DOI: 10.1111/hepr.13695] [Reference Citation Analysis]
13 Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int 2021;41:982-95. [PMID: 33283415 DOI: 10.1111/liv.14749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
15 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther 2021;54:1472-80. [PMID: 34694013 DOI: 10.1111/apt.16674] [Reference Citation Analysis]
17 Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu V, Bugianesi E, Anstee QM, Daly AK; LITMUS Consortium Investigators§., LITMUS Consortium Investigators. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Rep 2022;4:100409. [PMID: 35072021 DOI: 10.1016/j.jhepr.2021.100409] [Reference Citation Analysis]
18 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
20 Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol 2020;870:172913. [PMID: 31926994 DOI: 10.1016/j.ejphar.2020.172913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ghallab A, Myllys M, Friebel A, Duda J, Edlund K, Halilbasic E, Vucur M, Hobloss Z, Brackhagen L, Begher-Tibbe B, Hassan R, Burke M, Genc E, Frohwein LJ, Hofmann U, Holland CH, González D, Keller M, Seddek AL, Abbas T, Mohammed ESI, Teufel A, Itzel T, Metzler S, Marchan R, Cadenas C, Watzl C, Nitsche MA, Kappenberg F, Luedde T, Longerich T, Rahnenführer J, Hoehme S, Trauner M, Hengstler JG. Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. Cells 2021;10:2516. [PMID: 34685496 DOI: 10.3390/cells10102516] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Perez-Diaz-Del-Campo N, Marin-Alejandre BA, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI, Tur JA, Martinez JA, Abete I, Zulet MA. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. Eur J Nutr 2021;60:3043-57. [PMID: 33474638 DOI: 10.1007/s00394-020-02476-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 2020;. [PMID: 32544255 DOI: 10.1002/hep.31420] [Cited by in Crossref: 47] [Cited by in F6Publishing: 57] [Article Influence: 47.0] [Reference Citation Analysis]
25 Plaz Torres MC, Aghemo A, Lleo A, Bodini G, Furnari M, Marabotto E, Miele L, Giannini EG. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients 2019;11:E2971. [PMID: 31817398 DOI: 10.3390/nu11122971] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
26 De Chiara F, Ferret-Miñana A, Ramón-Azcón J. The Synergy between Organ-on-a-Chip and Artificial Intelligence for the Study of NAFLD: From Basic Science to Clinical Research. Biomedicines 2021;9:248. [PMID: 33801289 DOI: 10.3390/biomedicines9030248] [Reference Citation Analysis]
27 Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020;158:1913-28. [PMID: 32044315 DOI: 10.1053/j.gastro.2019.11.311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 23.5] [Reference Citation Analysis]
28 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
29 Lan T, Yu Y, Zhang J, Li H, Weng Q, Jiang S, Tian S, Xu T, Hu S, Yang G, Zhang Y, Wang W, Wang L, Zhu Q, Rong X, Guo J. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway. Hepatology 2021;74:686-703. [PMID: 33576035 DOI: 10.1002/hep.31749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ; American Association for the Study of Liver Diseases NASH Task Force. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021;73:2028-38. [PMID: 33111374 DOI: 10.1002/hep.31599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
31 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
32 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
33 Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, Shlomai A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 2020;158:1611-1625.e12. [PMID: 32027911 DOI: 10.1053/j.gastro.2020.01.043] [Cited by in Crossref: 150] [Cited by in F6Publishing: 143] [Article Influence: 75.0] [Reference Citation Analysis]
34 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatol Commun 2021;5:1810-23. [PMID: 34499435 DOI: 10.1002/hep4.1814] [Reference Citation Analysis]
35 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
36 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
37 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Bassegoda O, Olivas P, Turco L, Mandorfer M, Serra-Burriel M, Tellez L, Kwanten W, Laroyenne A, Farcau O, Alvarado E, Moga L, Vuille-Lessard E, Fortea JI, Ibañez L, Tosetti G, Vanwolleghem T, Larrue H, Burgos-Santamaría D, Stefanescu H, Paternostro R, Cippitelli A, Lens S, Augustin S, Llop E, Laleman W, Trebicka J, Chang J, Masnou H, Zipprich A, Miceli F, Semmler G, Forns X, Primignani M, Bañares R, Puente A, Berzigotti A, Rautou PE, Villanueva C, Ginès P, Garcia-Pagan JC, Procopet B, Bureau C, Albillos A, Francque S, Reiberger T, Schepis F, Graupera I, Hernandez-Gea V. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01136-8. [PMID: 34688952 DOI: 10.1016/j.cgh.2021.10.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Euh W, Lim S, Kim JW. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:613389. [PMID: 34177796 DOI: 10.3389/fendo.2021.613389] [Reference Citation Analysis]
41 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
42 Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 2020;21:1637-50. [PMID: 32543284 DOI: 10.1080/14656566.2020.1774553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
43 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Rowe IA, Parker R. The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00598-X. [PMID: 34091047 DOI: 10.1016/j.cgh.2021.05.059] [Reference Citation Analysis]
45 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Brunt EM, Clouston AD, Goodman Z, Guy C, Kleiner DE, Lackner C, Tiniakos DG, Wee A, Yeh M, Leow WQ, Chng E, Ren Y, Boon Bee GG, Powell EE, Rinella M, Sanyal AJ, Neuschwander-tetri B, Younossi Z, Charlton M, Ratziu V, Harrison SA, Tai D, Anstee QM. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.011] [Reference Citation Analysis]
47 Blagotinšek Cokan K, Urlep Ž, Moškon M, Mraz M, Kong XY, Eskild W, Rozman D, Juvan P, Režen T. Common Transcriptional Program of Liver Fibrosis in Mouse Genetic Models and Humans. Int J Mol Sci 2021;22:E832. [PMID: 33467660 DOI: 10.3390/ijms22020832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Reference Citation Analysis]
50 Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs 2020;29:89-92. [PMID: 31952447 DOI: 10.1080/13543784.2020.1718106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
51 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Ampuero J, Aller R, Gallego-Durán R, Crespo J, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Augustín S, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. Liver Int 2021;41:2076-86. [PMID: 33896100 DOI: 10.1111/liv.14898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hagström H, Bu D, Nasr P, Ekstedt M, Hegmar H, Kechagias S, Zhang N, An Z, Stål P, Scherer PE. Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scand J Gastroenterol 2021;56:437-42. [PMID: 33556256 DOI: 10.1080/00365521.2021.1879249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]